GMAB

Rating neutralTentativeAI Memo

Genmab A/S

As of 2026-08-05/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-08-05 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Report quality notice

high-coverage report lacks a dated company-specific catalyst beyond generic cadence; peer set is too generic or lacks enough direct operating comparators; memo remains a monitoring view with limited forward evidence and should not be standard-conviction

Action

neutral

Confidence

medium

Horizon

—

Key catalyst

European follicular-lymphoma label expansion • 2026-07-06

Base target: $29 / p=50% prob

Biggest risk

The DLBCL-1 U.S. overall-survival primary endpoint was not met, which is the most important recent negative signal. Upcoming DLBCL-2 data remain binary, while analyst estimate revisions, target changes, and consensus surprise data are unavailable.

Invalidation

Break below $25 or thesis failure.

What would change my mind?

DARZALEX worldwide net sales reached $4.207 billion in Q2 2026, supporting Genmab’s royalty engine, while the European TEPKINLY approval and positive DLBCL-4 PFS result broaden epcoritamab’s opportunity set. [#PR-EARNINGS-2026-07-15] [#IR-GMAB-TEPKINLY-2026-07-06]

Research note

Recommendation

neutral

Confidence

medium

As of

2026-08-05

Base target

$29

p=50%

Bull target

$38

p=25%

Bear target

$25

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

EPCORE DLBCL-1 U.S.
overall-survival endpoint miss remains the key overhang
DLBCL-4 regulatory and commercial follow-through

BearKey bullets

Analyst revisions, consensus surprise data, short interest, options data, and post-event price attribution are unavailable in the packet.
EPCORE DLBCL-1 did not meet its U.S.
overall-survival primary endpoint.

WatchKey bullets

European follicular-lymphoma label expansion

Summary

High-level snapshot

Recommendation

neutral

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $29 (p=50%)

Target spread vs base: +30% / -15%

Scenario probabilities

Bull Target: $38 (p=25%)Base Target: $29 (p=50%)Bear Target: $25 (p=25%)

Commentary

Recent primary-company news is mixed: positive TEPKINLY approval, DLBCL-4 PFS results, and DARZALEX sales are offset by the DLBCL-1 U.S. overall-survival endpoint miss. Coverage is high, but analyst revisions and post-event market-reaction attribution are unavailable; sentiment is therefore neutral with a cautious monitoring bias.

As of 2026-08-05 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

EPCORE DLBCL-1 U.S. overall-survival endpoint miss remains the key overhang
DLBCL-4 regulatory and commercial follow-through

Scenarios

Bull Target (Scenario probability)

$38 / p=25% prob

Base Target (Scenario probability)

$29 / p=50% prob

Bear Target (Scenario probability)

$25 / p=25% prob

Analysis 2026-08-05 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

45.00

Social Sentiment (7d)

Events

Other notable items detected

EVENT2026-07-06
European follicular-lymphoma label expansion
The European Commission approved TEPKINLY plus lenalidomide and rituximab for relapsed/refractory follicular lymphoma, creating a commercial expansion opportunity supported by positive Phase 3 efficacy data. [#IR-GMAB-TEPKINLY-2026-07-06]
Prob 100.00% • Move 6.00% • Priced-in 60.00%
EVENT2026-11-03
EPCORE DLBCL-2 2026 readout
Management stated that data from the Phase 3 EPCORE DLBCL-2 trial in newly diagnosed DLBCL are anticipated in 2026, creating a binary readout risk/opportunity after mixed epcoritamab evidence. [#IR-GMAB-DLBCL1-2026-07-23]
Prob 50.00% • Move 12.00% • Priced-in 35.00%

Short-term Catalysts

Next few weeks

EPCORE DLBCL-1 U.S. overall-survival endpoint miss remains the key overhang
2026-07-23
Genmab and AbbVie clarified that overall survival was the sole U.S. primary endpoint and was not met, leaving near-term sentiment vulnerable while investors reassess epcoritamab’s confirmatory-data profile. [#IR-GMAB-DLBCL1-2026-07-23]
Prob 85% • Move -8% • Priced-in 70%

Long-term Catalysts

Months to a year

DLBCL-4 regulatory and commercial follow-through
2026-06-29
The Phase 3 EPCORE DLBCL-4 trial met its PFS objective, reducing progression or death risk by 60% under the U.S. censoring rule; Genmab and AbbVie plan to engage global regulators. [#IR-GMAB-DLBCL4-2026-06-29]
Prob 65% • Move 10% • Priced-in 45%

Risks

Analyst revisions, consensus surprise data, short interest, options data, and post-event price attribution are unavailable in the packet.
EPCORE DLBCL-1 did not meet its U.S. overall-survival primary endpoint. [#IR-GMAB-DLBCL1-2026-07-23]
Epcoritamab’s future value remains dependent on additional clinical, regulatory, and commercial execution across indications.
Royalty exposure and reliance on partner-reported product sales create concentration and partner-execution risks.
Treatment-related safety and tolerability remain relevant as combination regimens expand; the EU approval release reported serious adverse reactions in 44% of combination-treated patients. [#IR-GMAB-TEPKINLY-2026-07-06]

Peers

Symbol	Summary
ASND	Similar-sized same-sector biopharma reference; useful for relative scale, but not a like-for-like comparison with Genmab’s oncology and royalty exposure.
JAZZ	Similar-sized same-sector commercial biopharma reference; therapeutic mix differs, so comparison is directional rather than direct.
GILD	Larger same-sector benchmark with a broader commercial base; useful for context but not a close size or business-model peer.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-08-05

Loading AI feed…

Symbol

Summary

ASND

Similar-sized same-sector biopharma reference; useful for relative scale, but not a like-for-like comparison with Genmab’s oncology and royalty exposure.

JAZZ

Similar-sized same-sector commercial biopharma reference; therapeutic mix differs, so comparison is directional rather than direct.

GILD

Larger same-sector benchmark with a broader commercial base; useful for context but not a close size or business-model peer.